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ABSTRACT 
 
The poor correlation of mutational landscapes with phenotypes limits our understanding of pancreatic 
ductal adenocarcinoma (PDAC) pathogenesis and metastasis. Here we show a critical role of oncogenic 
dosage-variation in PDAC biology and phenotypic diversification. We found gene-dosage increase of 
mutant KRASMUT in human PDAC precursors, driving both early tumorigenesis and metastasis, thus 
rationalizing early PDAC dissemination. To overcome limitations posed to gene-dosage studies by 
PDAC´s stroma-richness we developed large cell culture resources of metastatic mouse PDAC. 
Integration of their genomes, transcriptomes and tumor phenotypes with functional studies and human 
data, revealed additional widespread effects of oncogenic dosage-variation on cell 
morphology/plasticity, histopathology and clinical outcome, with highest KrasMUT levels underlying 
aggressive undifferentiated phenotypes. We also identify alternative oncogenic gains (Myc, Yap1 or 
Nfkb2), which collaborate with heterozygous KrasMUT in driving tumorigenesis, yet with lower metastatic 
potential. Mechanistically, different oncogenic gains and dosages evolve along distinct evolutionary 
routes, licensed by defined allelic states and/or combinations of hallmark tumor-suppressor alterations 
(Cdkn2a, Trp53, Tgfb-pathway). Thus, evolutionary constraints and contingencies direct oncogenic 
dosage gain and variation along defined routes to drive early progression and shape downstream PDAC 
biology. Our study uncovers universal principles in Ras-driven oncogenesis with potential relevance 
beyond pancreatic cancer. 
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Pancreatic ductal adenocarcinoma (PDAC) is the fourth leading cause of cancer-related death and is 
expected to become the second within the next decade1. Whilst treatments constantly improved for 
many other cancer types, 5-year survival rates in PDAC stayed around 5%1. Genome sequencing 
revealed extensive genetic heterogeneity beyond a few frequently mutated drivers2-8 like KRAS, TP53, 
CDKN2A or TGFb-pathway alterations. Disappointingly however, genomic changes could so far not be 
broadly linked to biologic, morphologic or clinical phenotypes. In addition, the molecular basis of cancer 
cell dissemination is poorly understood, and genetic comparisons of primary/metastasis pairs could not 
identify recurrent alterations linked to metastasis3,8. Critical limitations to human PDACs (hPDAC) 
genomics are (i) the cancer genome complexity, posing challenges to their interpretation, (ii) the high 
(and variable) stromal content, which confounds particularly gene-dosage analyses and transcriptome 
interpretation, (iii) the limited availability of human cell culture-based resources to overcome this problem 
and (iv) the scarcity of paired primary/metastasis tissues, particularly of treatment-naive ones, e.g. for 
evolutionary studies. Here we characterized large murine PDAC cell line resources and combined the 
results with cross-species comparisons and functional studies to unravel molecular principles underlying 
PDAC evolution and phenotypic diversification.  
 
Genetic landscapes of mouse PDAC 
 
We initially characterized primary PDAC cell cultures from 38 mice expressing KrasG12D conditionally in 
the pancreas (PK mice)9,10 by multiplex FISH (M-FISH), whole-exome sequencing (WES) and array 
comparative genomic hybridization (aCGH). We developed a pipeline for WES data analysis allowing 
mouse/human comparisons using identical parameter settings. A WES study on microdissected human 
PDAC (reduced stromal “contamination”) served as the reference human data set6. Somatic mutation 
calling identified 318 synonymous and 606 non-synonymous mutations in 38 mPDACs (Extended Data 
Fig. 1a and Supplementary Table 1). Mutational patterns were similar, (Fig. 1a; Supplementary Table 
2, Extended Data Fig. 1b-g) but mutational burdens were significantly higher in hPDAC than mPDAC, 
with 3.3 and 1.5 fold increased median SNV and indel numbers, respectively (Fig. 1b and 
Supplementary Tables 1, 3-5). Recurrently altered genes were infrequent in mice. A subset overlapped 
with recurrently mutated genes in human cancers and/or common insertion sites in pancreas-specific 
transposon screens11-13 (Extended Data Fig. 1a).  
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Structural changes were also less common in mPDAC (Fig. 1b, Supplementary Tables 6-8). There was 
however substantial variation between cancers, with some mPDACs having only few focal alterations, 
but others showing extensive changes, including clustered intra-chromosomal alterations, aneuploidy 
and inter-chromosomal translocations (Fig. 1c and Extended Data Fig. 1h-l). Notably, 34% (14/38) 
tumors had complex rearrangements, with ten or more alterations per affected chromosome. The 
majority (12/14) of such events affect chr4, invariably involving Cdkn2a. One cancer showed massively 
rearranged chr15 with high-level Myc amplification and another tumor had clustered chr1 
rearrangements (Extended Data Fig. 2a-n). These findings reflect selection of complex rearrangements 
that affect cancer drivers.  
 
The regularity of oscillating copy number states in most cancers suggested chromothripsis as the 
predominant process underlying these complex alterations. Whole-genome sequencing, followed by 
rearrangement analysis and computational simulations confirmed all hallmarks defining the one-off 
nature of chromothripsis14, including clustering of breakpoints, regularity of oscillating copy number 
states, identical CNA and LOH patterns, randomness of DNA segment order/joints and alternating head-
tail sequences (Fig. 1d and detailed analyses in Extended Data Fig. 2p-y. In addition, M-FISH confirmed 
chr4 content loss affecting only one haplotype (Fig. 1d).  
 
Complex rearrangements were proposed to trigger accelerated evolution of human PDAC15. The mouse 
model allows experimental interrogation of this hypothesis due to the “synchronized” nature of tumor 
initiation (KrasG12D-mutation). We found that time-to-tumor development was indeed shorter in animals 
with Cdkn2a loss through catastrophic events (Fig. 1e and Extended Data Fig. 2o). A subset (16%) of 
complex rearrangements in hPDAC disrupts multiple known tumor suppressors through 
translocations15. Chromothripsis-associated chr4 translocations were also frequent in mice (Fig. 1c), 
although no recurrent translocation partners were found.  
 
KrasMUT-iGD links early progression & metastasis 
 
The most common amplification affected the Kras locus (Extended Data Fig. 3a,b), which is also 
frequent in hPDAC16,17. Combined analyses of M-FISH, aCGH and Kras mutant/wild-type (wt) allele 
frequencies revealed four different KrasG12D gene dosage "states" (Fig. 2a, Extended Data Fig. 3c-h and 
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Supplementary Table 9): focal gain (KrasG12D-FG, 7.9%), arm-level gain (KrasG12D-AG, 23.7%), copy 
number neutral loss of wt Kras (KrasG12D-LOH, 36.8%) or no change (KrasG12D-HET, 31.6%). Thus, two 
thirds of cancers had allelic imbalances causing increased KrasG12D gene dosage (hereafter designated 
KrasG12D-iGD), suggesting strong selective pressure for its acquisition. In addition, two KrasG12D-HET tumors 
displayed loss of KrasWT-mRNA, but high KrasG12D expression (blue dots in Fig. 2b), suggesting 
additional non-genetic mechanisms. Of note, we observed similar KRASG12D-iGD rates/types in human 
PDAC cell lines (Supplementary Table 10). Gene dosage increase affects transcriptional output, as 
KrasG12D-iGD mPDAC had higher KrasG12D mRNA expression than KrasG12D-HET cancers (Fig. 2b and 
Extended Data Fig. 3i).  
 
Ras/Raf signaling amplification was observed at different stages of mammary, intestinal or lung 
tumorigenesis18-21. To identify the stage of KRASMUT-iGD-acquisition in PDAC, we microdissected low-
grade human pancreatic intraepithelial neoplasias (hPanIN) from 19 patients and performed amplicon-
based deep sequencing of KRAS exon-2 (Fig. 2c and Supplementary Table 11/12). hPanIN with exon-
2-mutated KRAS (20 out of 40 hPanINs featured KRASG12 mutations) displayed frequent KRASMUT-iGD: 
KRASMUT allele frequencies >50% occurred in 50%, 38% and 67% of KRAS exon-2-mutated hPanIN1a, 
hPanIN1b and hPanIN2, respectively. Given that healthy tissue "contamination" rates in microdissected 
PanINs ranged between 10-60%, KRASMUT-iGD is likely to be even more frequent. In cases with close to 
100% mutant read frequency, KRAS interphase FISH excluded false-positive KRASG12D-iGD arising 
through chr12 monosomy (Extended Data Fig. 3l-n). Moreover, false-positive KRASMUT-iGD through 
cross-“contaminating” hPDAC is excluded due to either (i) the large distance of selected hPanINs to 
associated cancers, (ii) distinct KRAS mutations in hPanINs and associated cancers, or (iii) KRASMUT-
iGD in IPMN-related hPanINs without invasive hPDAC. Altogether, these data suggest a critical role of 
KRASMUT-iGD in early PDAC progression.  
 
Looking at organ dissemination, we found a dramatically increased metastatic potential of KrasG12D-iGD 
cancers (OR 16.7; 95% CI 2.8-98.0; Fig. 2d): primary mPDACs with KrasG12D-iGD were mostly 
metastasized (20/26), whereas KrasG12D-HET mPDACs were predominantly non-metastatic (2/12). Thus, 
KrasG12D-iGD drives both early progression and metastasis. This dual role explains (i) early PDAC 
dissemination in humans and mice22 and (ii) the high incidence of human PDAC metastasis at 
diagnosis23. We also mined published data8,24 and invariably found KRASMUT-iGD in human PDAC 
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metastases. However, because KRASMUT-iGD is present in the primary (early acquisition), its contribution 
to metastasis could not be recognized by primary/metastasis comparisons8.  
 
Alternative oncogenic gains in KrasMUT-HET tumors 
 
Among the 12 cancers without KrasG12D-dosage gain, two cases had Myc amplifications and two had 
Yap1 gains (Fig. 2e and Extended Data Fig. 4a-d). MYC and YAP1 are known human oncogenes, 
amplified in 12% (13/109) and 1% (1/109) of hPDAC, respectively (Fig. 2f). In addition, chr19 gain 
occurred more frequently in KrasG12D-HET (3/12) than KrasG12D-iGD tumors (4/26), although this was not 
significant. A focal amplification on chr19 contained 20 genes (Extended Data Fig. 4e). Cross-species 
analyses revealed frequent gains of the syntenic region in hPDAC, with two genes in the minimal peak 
region: NFKB2 and PSD, both amplified in 7% (8/109) of hPDAC (Extended Data Fig. 4f). NFKB2 (but 
not PSD) is expressed in human pancreas and hPDAC (Extended Data Fig. 4g,h), suggesting Nfkb2 to 
be the target proto-oncogene on murine chr19. NFKB2 mediates non-canonical Nfkb signaling. It has 
not yet been associated with hPDAC, but promotes cell cycle progression in vitro25, and knockout of its 
interaction partner RelB impairs PanIN formation in PK mice26. Thus, upon Kras mutation, further 
amplification of partial aspects of Kras downstream signaling (Myc, Yap1 or Nfkb2) seem sufficient to 
drive early PDAC progression, whereas strong metastatic potential is linked to amplification of the full 
KrasG12D signaling program.  
 
Evolutionary licensing of oncogenic dosages  
 
The most frequent deletion in mPDAC affected Cdkn2a and/or the adjacent non-coding Cdkn2a-
regulatory region Ncruc: 23 Cdkn2aDHOM, 4 NcrucDHOM, 10 Cdkn2aDHET, 1 Cdkn2aWT (chr4 alteration types 
shown in Fig. 3a,b, Extended Data Fig. 5a-d and Supplementary Table 9). Notably, the majority of 
Cdkn2a/NcrucDHOM cancers were KrasG12D-iGD (23/27) and had high KrasG12D expression. In contrast, 
Cdkn2aDHET or Cdkn2aWT cancers were predominantly KrasG12D-HET (8/11) with low KrasG12D expression 
(Fig. 3c, Extended Data Fig. 3j and 5e,f). Accordingly, in microdissected human PDAC datasets6, 
KRASMUT variant allele frequencies were higher in CDKN2A∆HOM  than in CDKN2A∆HET/WT tumors (Fig. 
3d and Extended Data Fig. 5g). Thus, CDKN2A∆HOM-deletion and KRASMUT-iGD are linked, with two 
possible scenarios: (i) KRASMUT-iGD occurs first, but induces senescence that prevents progression until 
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CDKN2A is lost (as proposed in breast tumorigenesis18), or (ii) KRASMUT-iGD is only tolerated if preceded 
by CDKN2A deletion.  
 
To resolve the sequence, we determined copy-number changes and copy-number neutral allelic 
imbalance at Cdkn2a and Kras in Cdkn2a∆HOM;KrasG12D-iGD mPDACs (n=13) and associated metastases 
(n=25). We found identical Cdkn2a deletions in all 13 primary/metastasis pairs, but discordant chr6 
CNA/LOH phenotypes in 7/13 pairs (Fig. 3e). In 6/13 pairs the sequence of Cdkn2a-loss/KrasG12D-iGD 
could not be reconstructed, either because the SNP density was too low (4 cases) or because chr6 
profiles in primary/metastasis pairs were identical (2 cases). Thus, in all cases with reconstructable 
sequence, Cdkn2a deletion preceded KrasG12D-iGD acquisition. For example, mPDAC-53704 (Extended 
Data Fig. 6) had two liver metastases with identical Cdkn2a deletions, but distinct chr6 SNP patterns: 
one with KrasG12D-LOH at distal chr6 (through mitotic recombination) and another affecting the whole 
chromosome (likely through missegregation). This confirms clonal chr6 diversification and convergent 
evolution following Cdkn2a loss, and explains the primary´s gradual chr6 SNP pattern (Extended Data 
Fig. 6). Fig. 3f shows another example: mPDAC 5320 and its three metastases had identical Cdkn2a 
deletions, but distinct chr6 patterns: while liver metastasis-1 had KrasG12D-AG (combined interpretation of 
aCGH and SNP data), liver metastasis-3 and the lung-metastasis had distinct KrasG12D-LOH events, again 
showing convergent evolution of Kras-allelic imbalance and explaining the primary´s composite SNP 
pattern (Fig. 3f).  
 
These results reveal several evolutionary principles in PDAC. First, KrasG12D-iGD is contingent on 
Cdkn2a∆HOM inactivation. Second, Myc, Yap1 or Nfkb2 amplifications can occur on a Cdkn2a∆HET 
context, suggesting context-dependent Cdkn2a haploinsufficiency. Of note, only one cancer was 
Cdkn2aWT. Third, evolution of multiple independent KrasG12D-gains in Cdkn2a∆HOM cancers 
demonstrates functional convergence towards KrasG12D-iGD acquisition upon homozygous Cdkn2a loss.  
 
To provide in vivo evidence for functional convergence in Cdkn2a∆HOM contexts, we generated mice with 
pancreas-specific KrasG12D-expression and Cdkn2a-deletion (PKC). We found KrasG12D-iGD in 100% 
(16/16) of PKC tumors (Fig. 4 and Supplementary Table 9), confirming that KrasG12D-iGD acquisition is 
the preferred evolutionary route upon homozygous Cdkn2a loss.  
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Another hPDAC hallmark is TP53 inactivation27. The analysis of cancers from KrasG12D-Panc;Trp53DPanc 
(PKP) mice revealed ubiquitous KrasG12D-iGD (16/16) (Fig. 4 and Supplementary Table 9). Thus, Trp53-
loss (like Cdkn2a∆HOM alteration) predisposes to KrasG12D-iGD acquisition (also reflected in hPDAC; 
Extended Data Fig. 5g). PK/PKC/PKP cross-comparisons revealed higher CNA numbers and a 
tendency to amplify KrasG12D through arm-level gain (trisomy) in PKP, whereas copy-number neutral 
LOH predominates in PKC (Fig. 4 and Extended Data Fig. 5h). Of note, PKP or PKC tumors did not 
have complex chr4 rearrangements, confirming that chromothripsis in PK cancers results from natural 
selection for Cdkn2a inactivation (Fig. 4).  
 
To address the role of the TGFb-pathway, we characterized KrasG12D-Panc;Tgfbr2DPanc (PKT) mice (Fig. 4 
and Supplementary Table 9). Strikingly, all PKT tumors (n=12) had Cdkn2a alterations: two cancers 
were Cdkn2a∆HOM/KrasG12D-iGD, ten were Cdkn2a∆HET and predominantly KrasG12D-HET (8/10). Overall, the 
prevalence of KrasG12D-iGD is significantly lower in PKT (4/12) than PK mice (26/38) (P=0.04, Fisher’s 
exact test, OR 0.23, 95% CI 0.06-0.92). KrasG12D-HET cancers had frequent alternative oncogenic gains 
(Nfkb2/chr19 trisomy in 4/8 PKT mice), similarly to KrasG12D-HET cancers in the PK cohort. Thus, contrary 
to Trp53∆HOM or Cdkn2a∆HOM alterations, which license KrasG12D-iGD-acquisition, Tgfbr2 alterations 
facilitate the alternative route with Cdkn2a haploinsufficiency.  
 
Altogether these data show that evolutionary contingencies and convergence shape early 
tumorigenesis: different tumor suppressor genes/pathways (Cdkn2a, Trp53, Tgfb), their alteration types 
(∆HOM/∆HET) or their combinations (e.g. Cdkn2a∆HET/Tgfbr2∆HET) direct evolution into different 
trajectories by licensing distinct types and extents of oncogenic dosage gains.  
 
Integrating genomes, transcriptomes, phenotypes 
 
Unbiased hierarchical clustering of RNA-Seq data from mPDAC cell cultures (PK cohort) revealed two 
clusters C1/C2, with 3 sub-clusters within C2 (Fig. 5a). Pathway analyses identified “epithelial cell 
differentiation” as the top C2 GO-term, whereas “mesenchymal cell differentiation” was defining C1 (Fig. 
5a,b and Supplementary Table 13,14). Notably, all C1 cell lines show mesenchymal cell morphology, 
while C2 lines are invariably epithelial (Fig. 5a,c).  
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Previous studies classified human pancreatic cancer based on transcriptional profiles7,28,29. Unbiased 
hierarchical clustering with published classifiers shows large overlaps of subtypes proposed by Bailey7 
and Moffitt29 to the initially proposed three Collisson28 subtypes: classical, exocrine-like, 
quasimesenchymal (QM). One exception is the lacking exocrine-like signature in the Moffitt 
classification, which was proposed to be an artefact of acinar cell "contamination" (details in Extended 
Data Fig. 7a-d). The Collisson classifier28 separates human PDAC cell lines into two subtypes (classical 
and QM; Extended Data Fig. 7e) and mouse PDAC cell lines into 3 subtypes: classical-equivalent, QM-
equivalent (both in epithelial C2) and the mesenchymal M subtype (C1) (Extended Data Fig. 7f). The 
equivalent of the mouse M subtype with the strong EMT signature has not been described in human cell 
lines so far, reflecting underrepresentation of mesenchymal phenotypes in human cell line collections 
(see also Extended Data Fig. 7g,h). As described below, however, mesenchymal mPDACs in C1 
represent undifferentiated pancreatic carcinomas with a pronounced EMT signature and human 
equivalent.  
 
C1 shows strong gene set enrichment for Ras downstream signaling pathways (Fig. 5b and 
Supplementary Tables 13,14). This cannot be explained by the genetic Kras status alone: only C2a is 
KrasG12D-HET, whereas C2b, C2c and C1 are mostly KrasG12D-iGD. However, integration of KrasG12D 
expression revealed its gradual increase from C2a to C2b/c and further substantial elevation in C1 (Fig. 
5d and Extended Data Fig. 3k). Thus, the mesenchymal phenotype is associated with KrasG12D 
expression above a certain threshold.  
 
To study this association further, we induced clonal PDACs by CRISPR/Cas9 somatic mutagenesis30 in 
PK mice (Fig. 5e), screened for simultaneous presence of epithelial and mesenchymal cells, and 
separated/enriched either phenotype by differential trypsinization. Two such cancers were identified. In 
each case, indel patterns of epithelial/mesenchymal pairs were identical (Extended Data Fig. 8a,b), 
showing (i) common clonal origin of epithelial/mesenchymal cells and (ii) independence of 
epithelial/mesenchymal phenotypes form CRISPR/Cas9-induced TSG alterations. Notably however, 
mPDAC 021 had KrasG12D-iGD, elevated Kras expression and downstream pathway activation in 
mesenchymal, but not epithelial cells. In mPDAC 901 both clones were KrasG12D-HET, but mesenchymal 
cells had increased Kras expression, supporting a role of KrasG12D dosage-variation in shaping cellular 
phenotypes (Fig. 5e, Extended Data Fig. 8c,d and Supplementary Table 15). Moreover, KRASG12D 
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overexpression in hPDAC cell lines induced an EMT signature, with Vimentin upregulation and E-
cadherin repression (Extended Data Fig. 8e-g and Supplementary Table 16).  
 
PDAC histology revealed a striking association with transcriptome clusters (Fig. 5a,f). Histopathologic 
grade scores increased from C2a to C2b/c and C1, with C2a being well- or moderately differentiated 
(G1, G2) and C1 being almost exclusively undifferentiated. Undifferentiated cancers are typically 
advanced and therefore underrepresented (1-3%) in human surgical series or cell line collections, but 
autopsy series reported up to 16% hPDACs with at least focal undifferentiated components31,32. 
Dedifferentiation can occur during disease progression or is triggered by treatment. It is associated with 
poor prognosis32,33, which is also reflected in mice (Extended Data Fig. 9a). Our results link this 
aggressive PDAC subtype with highest KrasG12D expression levels and Ras-related transcriptional 
programs (Fig. 5b,d and Supplementary Table 13). We also screened human transcriptome data (ICGC 
PACA-AU cohort) for undifferentiated pancreatic carcinomas and performed unbiased hierarchical 
clustering of differentially regulated genes in undifferentiated cancers (Extended Data Fig. 9b). Of note, 
undifferentiated human pancreatic carcinomas are characterized by reduced expression of genes 
involved in “epithelial” (cluster-2) or “squamous differentiation” (cluster-1), and a strong upregulation of 
genes in cluster-3, containing gene sets enriched for EMT and Ras downstream signaling (Extended 
Data Fig. 9b-d and Supplementary Table 17 and 18).  
We exploited the mouse to address complex questions, including cell based resources (overcoming 
human PDAC´s stroma richness), primary/metastasis resources (phylogenetic tracking, evolution) and 
in vivo modelling (proof-of-concept functional studies). In addition, discoveries were facilitated by the 
relatively low complexity of mouse PDAC genomes (easier interpretability). Notably, a transposon-
induced PDAC model13 showed that our findings are equally valid in contexts of excessive mutational 
loads (Extended Data Fig. 10 and Supplementary Table 19). 
 
Conclusions 
Our study proposes a novel comprehensive conceptual framework for molecular PDAC evolution and 
phenotypic diversification. It describes evolutionary trajectories, identifies their genetic hallmarks and 
shows how oncogenic dosage-variation is differentially licensed along individual routes by the three 
major PDAC tumor suppressive pathways to control critical disease characteristics, including early 
progression, histopathology, metastasis, cellular plasticity and clinical behavior (Fig. 5g). RAS gene 
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mutations affect more than 30% of human cancers, often involving their allelic imbalance. We therefore 
presume that the principles identified here are significant far beyond PDAC.  
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Figure 1 | Genetic landscape of mouse PDAC and comparison to the human disease. a, 
Trinucleotide context-dependent SNV frequencies in mouse (n=38 PK mice) and human PDAC (n=51 
patients from6) derived from WES. b, SNV, indel, CNA and translocation burdens by WES, aCGH and 
M-FISH in PK mice (n=38) and human PDAC (n=51 patients for SNV, indel, CNA [data from6] and n=24 
cell lines for translocations). **P=0.002, ***P≤0.001, two-sided Mann-Whitney test; bars, median. c, 
CNAs and ploidy/translocations in PK mice (n=38), detected by aCGH and M-FISH. Mixed ploidy, n≥3 
diploid/tetraploid cells in 10 karyotypes. d, Rearrangement graph showing chr4 chromothripsis in 
mPDAC S821, based on WGS. Haplotype-specific chromosome content loss confirmed by M-FISH 
(n=10/10 karyotypes). e, Age at tumor diagnosis of mice having cancers with (n=14) or without (n=23) 
complex/clustered chromosomal rearrangements (n≥10 CNAs/chromosome). Two-sided log-rank test.  
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Figure 2 | Mutant KRAS gene dosage increase occurs early in PDAC evolution and drives 
metastasis. a, KrasG12D gene dosage “states” defined by aCGH, WES and M-FISH (n=38 PK mice). 
Exemplary CNV-plot for each "state" on the right, y-axis, copy number b, Allele-specific KrasG12D mRNA 
expression in KrasG12D-iGD (n=26 mice) and KrasG12D-HET mPDACs (n=12 mice) by combined amplicon-
based RNA-Seq and qRT-PCR. *P=0.02, two-sided Mann-Whitney test; bars, median. c, Codon-12 
variant allele frequency of microdissected KRASG12 mutant hPanIN (n=20) by amplicon-based deep 
sequencing. H&E stains show histopathologic stages of microdissected hPanINs. Scale bars, 50 µm. d, 
Macro-/micro-metastasis prevalence in KrasG12D-HET (n=12) vs. KrasG12D-iGD (n=26) mPDACs. 
(***P=0.001, two-sided Fisher’s exact test). Liver metastasis, H&E. Scale bars, 150 µm (top) and 50 µm 
(bottom); square, zoom-in area. e, KrasG12D-HET mPDAC amplify alternative oncogenes (Myc, Nfkb2 or 
Yap1) to intensify partial aspects of Ras downstream signaling. Focal, focal amplification; Arm, arm-
level amplification. f, Amplification of MYC, NFKB2 or YAP1 in KRASMUT human PDAC. Note, these 
amplified genes can not only collaborate with KRASMUT-HET but also with KRASMUT-iGD. Data from6.  
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Figure 3 | Cdkn2a alteration “states” dictate distinct evolutionary PDAC trajectories. a, Chr4 
alteration types involving Cdkn2a by aCGH/M-FISH (n=38 PK mice). Complex rearrangements, n≥10 
CNAs/chromosome. Examplary CNV plots on the right; y-axis, copy number. b, Translocations affecting 
chr4/Cdkn2a in mPDAC-R1035 by M-FISH (10/10 karyotypes). c, Prevalence of KrasG12D-iGD in mPDAC 
with homozygously (∆HOM, n=27) vs. wild-type/heterozygously (∆HET/WT, n=11) deleted 
Cdkn2a/Ncruc. ***P=0.001, two-sided Fisher’s exact test, OR 15.3, 95% CI 2.8-83.9. d, KRAS variant 
allele frequencies in human PDAC with wild-type/heterozygously (n=56) vs. homozygously deleted 
(n=38) CDKN2A. Data from6. ***P≤0.001, two-sided Mann-Whitney test; bars, median. e, Sequential 
order of Cdkn2a and KrasG12D alterations. Chr4 and chr6 CNA/LOH patterns (based on aCGH,WES) of 
primary mPDACs (n=13 PK mice) and associated metastases (n=25). For seven mPDACs and 16 
associated metastases the order of genetic events (dots) could be reconstructed. Bifurcations, divergent 
evolution of clones; lines, lengths do not represent evolutionary distances; P, primary tumor; Li/Lu/LN, 
liver/lung/lymph node metastasis. f, Detailed chr4/chr6 CNV/LOH profiles for mPDAC5320 
primary/metastases. Cdkn2a deletions are identical in all lesions (y-axis, copy number). SNP frequency 
analysis by WES shows distinct chr6 SNP patterns in metastases and a composite picture in the primary, 
showing convergent evolution of different KrasG12D-iGD-gains upon Cdkn2a∆HOM. Scheme, combined 
interpretation of WES/aCGH data.  
  
 15 
 
Figure 4 | Defined allelic states and/or combinations of hallmark PDAC tumor-suppressor 
alterations license oncogenic dosage variation. Types and frequencies of KrasG12D gene dosage 
gains and Cdkn2a inactivations, defined by aCGH and amplicon-based KrasG12D sequencing in PDAC 
mouse models expressing pancreas-specific KrasG12D alone (PK) or in combination with engineered 
Cdkn2a∆HOM (PKC), Trp53∆HOM (PKP) or Tgfbr2∆HET/HOM (PKT) inactivation.  
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Figure 5 | Integrative analyses of PDAC genomics, transcriptomics, cellular phenotypes and 
histopathologies link molecular, morphologic and clinical disease characteristics. a, Unbiased 
hierarchical clustering of primary mPDAC culture transcriptomes (PK mice). Cell morphology, 
histopathological grading, KrasG12D mRNA expression, genetic KrasG12D status and presence/absence 
of metastasis integrated below. b, Selected gene sets from gene-set enrichment analysis of clusters C2 
vs. C1. (full list in Supplementary Table 13,14). c, mPDAC cultures with mesenchymal/epithelial 
morphology from clusters C1/C2, respectively. 100x magnification; squares, zoom-in area. d, KrasG12D-
allele-specific mRNA levels in mPDAC transcriptional clusters, combined amplicon-based RNA-Seq and 
qRT-PCR (C2a/b/c/C1, n=5/7/6/15 mice). P=1.9*10-6, two-sided Pearson correlation; bars, median. e, 
CRISPR/Cas9-mediated multiplexed somatic inactivation of PDAC-relevant tumor suppressors by 
electroporation-based transfection to achieve low-frequency mosaicism and clonal tumor outgrowth. 
Differential trypsinization separates epithelial/mesenchymal cells in mPDACs with mixed morphologies 
(100x magnification; squares, zoom-in area). CRISPR/Cas9-induced indel signatures are identical in 
epithelial/mesenchymal pairs (Extended data Fig. 8), indicating common cell of origin. Total Kras mRNA 
levels in epithelial/mesenchymal pairs (qRT-PCR, normalized to Gapdh, n=2 technical replicates). Bars, 
mean; error bars, SEM. f, mPDAC histophathological grading in transcriptional clusters (C2a/b/c/C1, 
n=4/7/6/15, single section per mPDAC). Representative sections (H&E) shown. *Benjamini-Hochberg-
adj. P≤0.05, **P=0.005; two-sided Fisher’s exact test; scale bars, 150µm. g, Simplified model of PDAC 
evolution reconciling molecular, morphologic and clinical disease characteristics. KRASG12D-iGD gain or 
alternative oncogenic amplifications (Myc/Yap1/Nfkb2) are critical for early disease progression. 
Different oncogenic gains and dosages evolve along distinct evolutionary routes, licensed by defined 
allelic states (heterozygous/homozygous) and/or combinations of hallmark tumor-suppressor 
alterations. For simplicity, only the prototype tumor suppressor gene CDKN2A is shown. Not visualized: 
TP53∆HOM loss, also promoting KRASMUT-iGD, or TGBFR2∆HET/HOM inactivation, supporting evolution 
through CDKN2AHET/KRASMUT-HET trajectories. Depicted trajectories are typical, but not completely 
exclusive, e.g. MYC or NFKB2 amplifications, which drive KRASMUT-HET cancers, can also cooperate 
with KRASMUT-iGD. Major aspects of a cancer´s biology/phenotype are linked to differential evolution.  
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METHODS  
Primary mPDAC cultures preparation. For 2D primary cell culturing, primary tumor or metastasis were 
cut into small pieces and digested 1-2h in 200Units/mL collagenase II (Worthington) in DMEM medium 
(Thermo Fisher Scientific Inc.) containing 10% fetal calf serum (FCS, Merck) and 1x 
Penicillin/Streptomycin (P/S, Thermo Fisher Scientific Inc.). After short term expansion, primary cells 
were frozen in 10% dimethyl sulfoxide (Roth) and 50% FCS. For all primary culture experiments, 
culturing medium (DMEM supplemented with 10% FCS and 1x P/S) and cultures with less than 10 
passages were used. Primary cultures were routinely tested for mycoplasma contamination by PCR and 
authenticated by re-genotyping of cell cultures and corresponding mice.  
gDNA and RNA isolation. gDNA from murine primary cell culture pellets was isolated using the DNeasy 
Blood & Tissue Kit (Qiagen) according to manufacturer’s instructions. Total RNA was isolated with the 
RNeasy kit (Qiagen) from 60-80% confluent primary cell lines cultured in a 10cm dish in culturing 
medium without P/S and immediately transferred into RLT buffer (Qiagen) containing ß-
mercaptoethanol.  
Histology and micro-metastases screening. For histologic characterization of mPDACs, 2µm thick 
specimens from formalin-fixed paraffin embedded (FFPE) material were routinely H&E stained and 
submitted to two veterinary pathologists experienced in comparative pancreatic cancer pathology. 
Histopathologic grading was performed with respect to the most recent consensus report of genetically 
engineered mouse models34. For histopathologic examination of micro-metastases, three H&E-stained 
liver sections (separated by 200µm) were screened for metastatic lesions by a veterinary pathologist.  
Animal experiments. Mice were maintained on C57Bl/6;129S6/SvEv mixed background and housed 
under specific-pathogen-free conditions. Female and male mice were randomly submitted to respective 
tumor cohorts. For the generation of double- or triple-mutants, pancreas-specific Cre lines10,35,36 were 
intercrossed with KrasG12D-Panc (PK mice)9,10 only, or in addition with Cdkn2a∆HOM-Panc (PKC mice)37, 
Trp53∆HOM-Panc (PKP mice)38,39 or Tgfbr2∆HET-Panc and Tgfbr2∆HOM-Panc (PKT mice)40 mice. Kaplan-Meier 
survival curves were generated using Prism (GraphPad Software v5.01). In case the animal presented 
a palpable abdominal mass above 1.5cm, ascites, signs of sickness or a weight loss of more than 15% 
of the body weight, mice were euthanized in compliance with the European guidelines for the care and 
use of laboratory animals. For necropsy of tumor-bearing mice, the abdominal cavity was 
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macroscopically checked for pancreatic cancer and for metastases at the main metastatic routes (liver, 
lung, lymph nodes). Animal studies were approved by the Institutional Animal Care and Use Committees 
(IACUC) of Technische Universität München (Regierung von Oberbayern, Munich, Germany).  
Amplicon-based deep sequencing at the Kras locus or of Kras mRNA. Fifty ng of high-quality 
genomic DNA or reversely transcribed mRNA (cDNA) were subjected to amplicon-based deep 
sequencing. Briefly, the KrasG12D-mutated locus was amplified using Q5® High-Fidelity DNA 
Polymerase (New England Biolabs, 40 cycles) and primers with Nextera adapter overhangs 
(Supplementary Table 20). In a second Q5® PCR step (15 cycles), Nextera index primers (Illumina) 
were added. After each PCR step, solid phase reversible immobilization cleanup (0.8x) was performed 
using the Agencourt® AMPure® XP kit (Beckman Coulter GmbH). The pooled library was quantified by 
SYBR® Green qPCR (Thermo Fisher Scientific Inc.) and the Kapa Biosystems library quantification kit. 
In total, 8pM of denatured library (20% spiked PhiX DNA) was sequenced in 300bp paired end mode 
using a MiSeq system (Illumina). Raw reads were mapped to Kras reference sequence (Ensemble 
release GRCm38p4, Genome Reference Consortium). Variant allele frequencies on chr6 at position 
145246771 were calculated.  
Microdissection of hPanIN and KRASG12 status analysis. Nineteen patients (Supplementary Table 
11) with or without a history of pancreatic cancer were included into hPanIN lesion analysis, according 
to approval by the Ethics Committee of the Faculty of Medicine of the Technische Universität München. 
Patients were classified using WHO recommendations and the TNM staging system. Serially cut 10µm 
thick specimens from FFPE material were air-dried overnight. Paraffin was removed through short 
incubation with xylene. Specimens were briefly stained with hematoxylin and kept wet for the micro-
dissection procedure. Individually diagnosed samples were microdissected under the Axio Imager 
microscope (Zeiss) using 20 gauche cannula. Pre- and post-sampling microscopic pictures were taken 
to (i) document dissection performance and (ii) re-identify each specimen on the corresponding H&E-
stained slide. gDNA was extracted as described above using MinElute spin columns (Qiagen) for higher 
sample concentration. Five µl of eluted hPanIN gDNA were submitted to amplicon-based deep 
sequencing of KRAS exon-2 for detection of KRASG12 hotspot mutations. Briefly, 2 pairs of custom KRAS 
primers (Supplementary Table 20) were used for nested PCR amplification of the corresponding KRAS 
region. Illumina Nextera primer pairs were used to add sequencing adapters and indices. PCR steps, 
library quantification and sequencing were performed as described above. Raw reads were mapped to 
 22 
 
KRAS reference sequence (GRCh38.p10). Variant allele frequencies were calculated for KRASG12 
hotspot mutations (positions 25398284 and 25398285 on chr12).  
Whole genome sequencing (WGS). One µg of high-quality gDNA extracted from primary tumor cell 
line and corresponding tail were sheared on a Covaris M220 focused ultrasonicator (Covaris, Inc.) to an 
approximate fragment size of 500bp. Library was prepared from 500ng of fragmented gDNA using the 
NEBNext® Ultra™ II DNA Library Prep Kit (New England Biolabs, Inc.) in combination with the 
adapter/primer sequences and PCR conditions published before41. The final library was quantified by 
qPCR using the Kapa Biosystems library quantification kit. Equimolar amounts of indexed libraries were 
denatured and diluted to a final concentration of 1.8pM and sequenced in 300bp paired end mode on a 
NextSeq 500 system (Illumina) to ~20x coverage. Sequencing raw data were converted to fastq format 
using the bcl2fastq software v2.18.0.12 (Illumina). Raw reads were trimmed with Trimmomatic v0.36 to 
preserve an average base Phred quality of 25, mapped using the BWA-MEM algorithm v0.7.12 with 
alternative contig handling and mapped to GRCm38.p5 reference genome.  
Inference of chromothripsis. For estimation of copy number states, the Bioconductor HMMcopy 
package 1.16.0 was used followed by segmentation with the Bioconductor DNAcopy package 1.48.0. 
For LOH analysis variant positions in control and tumor were computed with samtools mpileup v1.3.1. 
Only positions in regions with mapping quality of 60 and an average phredscore of 20 were considered 
for further analysis. Furthermore, positions harboring strand bias and variant allele frequencies less than 
20% and above 85% in the control were excluded as they are likely homozygous in the germline. The 
minimal cutoff coverage for a given polymorphic position in the control was set to eight reads. Segmental 
duplications (UCSC Genome Browser) and regions with mouse line specific variation (Mouse Genomes 
Project, REL-1505) were excluded. For this set of somatic nucleotide polymorphisms (SNPs) the 
difference of frequencies between tumor and control samples were calculated. DELLY v0.7.6 was used 
for calling structural variations (SVs). SV-classes were defined according to DELLY callings: Deletion-
type (3to5), duplication-type (5to3) and inversion-type (5to5 and 3to3). The predicted rearrangements 
were merged and filtered based on variant frequency, mapping quality and the distance between two 
connected breakpoints. The existence of chromothripsis was tested by applying the six hallmark criteria 
proposed by Korbel et al.14. Clustering of SV breakpoints was tested using a χ²-goodness-of-fit test. 
Regularity of oscillating copy number states in the chromothriptic model was compared to a virtual 
chromosome generated by a Monte Carlo simulation, as described in42. For each distinct number of 
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breakpoints, 100 simulation runs were completed and mean values as well as 95% CI were calculated. 
Interspersed loss and retention of heterozygosity was analyzed by calculating the Jaccard index 
between heterozygously deleted segments and regions comprising LOH and SNP information. 
Randomness of observed DNA segment order was tested using a Monte Carlo simulation as described 
in14. The uniform distribution of SV-types was tested using a χ²-goodness-of-fit test. The Wald-Wolfowitz 
runs test as implemented in R package randtests 1.0 was performed for testing right-sided against the 
null hypothesis of randomly distributed 5’-to-3’ breakpoint joints sequence.  
FISH analyses. For the analysis of copy number status or large structural alterations of human and 
murine primary cell lines, multicolor fluorescence in situ hybridization (M-FISH) was performed as 
described before43. For KRAS gene detection in hPanIN specimens, the ZytoLight® SPEC 
KRAS/CEN12 Dual Color Probe kit was used according to manufacturer’s instructions (ZytoVision 
GmbH). In brief, 2µm FFPE specimens were deparaffinized, pre-incubated in CC 2 buffer (at 95°C for 
24min), treated with pepsin solution (at 37°C for 8min) and denatured by a heat treatment step at 80°C 
for 8min on an automated Discovery XT system (Ventana Medical Systems, Inc.). KRAS/CEN12 dual 
color probe hybridization was performed by co-denaturing at 75°C for 10min and by incubating at 37°C 
overnight in a ThermoBrite system (Abbott Laboratories). Slides were washed, nuclei stained with 4',6-
diamidino-2-phenylindole (DAPI), covered in an antifade mounting medium and by a coverslip and 
stored for confocal laser scanning microscopy (LSM) analyses at 4°C in the dark. ZytoLight® SPEC 
KRAS/CEN12 Dual Color Probes and DAPI nuclear stain (excitation/emission: DAPI 405nm/415-
490nm; ZyGreen, 503nm/510-540nm; ZyOrange, 547nm/560-650nm) were detected by confocal LSM 
using a Leica TCS SP8; DMi8 CS microscope equipped with a 63x/1.4 oil immersion objective (Leica). 
Images (z-stacks, covering the whole nucleus) with a magnification factor of 3 and a frame size of 2048 
x 2048 pixels were collected. Generated images were processed using the Huygens Essential software 
(Scientific Volume Imaging) for deconvolution, than merged and maximum projections were converted 
with Leica LAS X software. 
aCGH analysis. Agilent oligonucleotide aCGH (SurePrint G3 Mouse CGH 240K or custom 60K 
microarray) was performed according to manufactures instructions. Agilent Genomic Workbench 
software v7.0.4.0 was used for aCGH data preprocessing. Legacy centralization option was used for re-
centralization of raw log ratios to the most common ploidy state. ADM-2 algorithm was applied for 
aberration calling. Segments coordinates were reported for GRCm37 reference genome. Aberrations 
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on chromosome 6 between positions 148719747 and 149503634 were excluded in further downstream 
analysis as this region resulted likely from an artefact. Normalized and curated data was imported into 
R.  
Whole-exome sequencing (WES) analysis. Coding exons were enriched via whole-exome pull down 
using Agilent SureSelect Mouse Exon Kit according to manufacturer's instructions and sequenced on 
the Illumina HiSeq2000 system. Prior to mapping, raw sequencing reads were trimmed using 
Trimmomatic v0.33. Leading and trailing bases with phred scores below 25 and reads shorter 50 
nucleotides were removed. In addition the average base quality within a sliding window of 10 nucleotides 
should be above 25 to keep the read for further downstream analysis. Reads were aligned to the 
GRCm38.p3 reference genome using BWA-MEM 0.7.12 with default settings. PCR duplicates were 
marked with Picard tools v1.130 and realignment around indels was performed with GATK toolkit v 
3.4.46. Mutect v 1.1.7 was used for calling somatic mutations with default settings. Potential somatic 
events were filtered for SNPs by excluding SNVs which were listed in in release 1505 of the Mouse 
Genome Project SNP database44. Somatic point mutations were included in the final list, if the read 
coverage for each position was ≥10 in both control and tumor, variant frequency was ≥10% and read 
count supporting the variant nucleotide is ≥3 in the tumor sample and =0 in the control. Further, SNVs 
marked as strand or PCR bias artifacts by "DKFZBiasFilter" (https://github.com/eilslabs/DKFZBiasFilter, 
using default settings) or with a FOXOG-Score of 1 were excluded. Annotation of somatic events was 
conducted with SNPeff v4.1. SNVs causing variation in splice sites or upstream/downstream of genes 
were excluded from further analysis. Indels were detected with Pindel45. For each potential indel the 
read coverage was re-calculated using bedtools v2.17.0. Criteria for further downstream processing 
were: Variant frequency ≥10% in tumor and =0% in control; and total coverage at the altered position in 
both control and tumor ≥20. LOH analysis was conducted as described in chapter Inference of 
Chromothripsis.  
WES data analysis from hPDAC. Mapped BAM files from Witkiewicz et al.6 were downloaded from the 
Sequence Read Archive (accession number PRJNA278883) approved by the Ethics Committee of the 
Faculty of Medicine of the Technische Universität München. Further downstream analysis was 
performed as described above. SNPs were filtered by excluding variants with an alternate allele 
frequency ≥1% in the 1000 Genomes Project, as listed in dbSNP build 146. All available VCF files from 
the TCGA-PAAD cohort generated by Mutect2 were downloaded from the NIH Genomic Data Commons 
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data. Downstream processing was performed as described above (PCR and strand bias marking by 
DKFZBiasFilter was not possible using VCF files). SNPs were filtered by excluding variants with an 
alternate allele frequency ≥1% in the 1000 Genomes Project, as listed in dbSNP build 142. MAF files 
from other human pancreatic cancer cohorts were downloaded and included in our analysis: All 
samples, for which whole-exome sequencing data was available, as provided by Bailey et al.7; 
pancreatic cancer cell lines from the Cancer Cell Line Encyclopedia46 and SNV data from pancreatic 
cancers as analyzed by Alexandrov et al.47. In these cohorts, SNPs were filtered by excluding variants 
with an alternate allele frequency ≥1% in the 1000 Genomes Project, as listed in dbSNP Build 146. 
Remaining SNVs were annotated and filtered with SNPeff as described above.  
Analysis of mutational signatures. Mutation spectra for each cohort were compared to a list of 21 
signatures previously described by Alexandrov et al.47; Signature 1B was excluded from further analyses 
because of presumed biological similarity to Signature 1A. The contribution of each individual signature 
to the mutation spectrum of each cohort was analyzed by using “deconstructSigs” v1.8.0.  
qRT-PCR analysis. Reverse transcription was performed with random hexamers using 1µg of total 
RNA following instructions of the SuperScript II protocol (Thermo Fisher Scientific Inc.). Real-time qPCR 
was performed either with the TaqMan qPCR chemistry (Thermo Fisher Scientific Inc.) for mouse using 
Kras-specific primers and probes or with the SYBR® Green master mix (Thermo Fisher Scientific Inc.) 
using primers for human target genes VIM, CDH1 and MMP1 (Supplementary Table 20). Gapdh or 
GAPDH in combination with PPIA were used as housekeeping genes for normalization (Supplementary 
Table 20). qPCR was conducted on a StepOnePlus system (Applied Biosystems). For analyses of 
mutant KrasG12D mRNA levels in mPDACs, first total (wild-type plus mutant) Kras mRNA levels were 
determined using qRT-PCR. Second, the identical cDNA was used for amplicon-based deep 
sequencing to detect the proportion of mutant to wild-type Kras mRNA. Third, the mutant to wild-type 
Kras mRNA ratio was multiplied with the total Kras mRNA level to calculate the mutant KrasG12D-specific 
mRNA level.  
RNA-Seq analysis. Bulk 3’-prime transcript end RNA-Seq (SCRB-Seq) libraries were prepared as 
described previously48. Briefly, RNA was reversely transcribed using oligo-dT primers decorated with 
sample barcodes, unique molecular identifiers (UMIs) and adapters (Integrated DNA Technologies). 
cDNA from all samples was pooled and un-incorporated primers digested using ExonucleaseI (New 
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England Biolabs). Next, the cDNA pool was amplified with KAPA HiFi ReadyMix (KAPA Biosystems). 
To obtain sequencing libraries, 0.8ng of cDNA was tagmented and 3’ ends amplified with the Nextera 
XT Kit (Illumina) using a specific primer for the adapter on the 3’-end. The library was paired-end 
sequenced on a HiSeq1500 with 16 cycles for read 1 to decode sample barcodes and UMIs and 51 
cycles on read 2 into the cDNA fragment. For the preparation of the human pancreatic cancer cell line 
samples, the flow cell binding sites P5 and P7 were exchanged to allow sequencing of the cDNA in 
read1 and barcodes and UMIs in read2.  Data was processed using the published Drop-seq pipeline 
(v1.0)49 to generate sample- and gene-wise UMI tables. Reference genome (GRCm38) was used for 
alignment. Transcript and gene definitions were used according to the ENSEMBL annotation release 
75. Further analyses were performed with R version 3.2.2. Initial hierachical clustering (method: 
Complete linkage, distance measure: Euclidian) of samples was performed for the top 10% variable 
genes. Bootstrapping was performed to access cluster stability with the pvclust package v2.0. The 4 
most prominent clusters were selected and differential expression between these clusters was 
calculated with DEseq250. A gene was considered to be differentially regulated if the absolute log2-
foldchange was above 0.8 and the adjusted P-value was ≤0.05. Gene set enrichment testing was 
performed with DAVID 6.851 or the hypergeomtric test as implemented on the “Molecular Signature 
Database” (MSigDB) v6.0 homepage (http://software.broadinstitute.org/gsea/msigdb/annotate). For all 
MSigDB analyses, top100 enriched terms with a false discovery rate (FDR) of P≤10-4 were included. 
Published PDAC classifier genes28 and the hallmark EMT gene set (downloaded from MSigDB v5.252) 
were used for sample clusterings (method: Ward, distance measure: Euclidian).  
hPDAC subtyping. Normalized RNAseq data was derived from Bailey et al.7. Samples that were 
histologically classified as “PDA-Adenosquamous carcinoma” and “Pancreatic Ductal Adenocarcinoma” 
were used for hierarchical clustering (method: Ward, distance measure: Euclidian) with classifier gene 
lists published elsewhere28,29.  
Microarray data analysis. Affymetrix-based CCLE raw data set was downloaded from (Broad-Novartis 
Cancer Cell Line Encyclopedia, Version 2.17). Hematopoietic or lymphoid neoplasms were excluded 
since (1) the primary interest of our study were solid tumors and (2) the overall gene expression 
signature of these samples was shown to be very distinct from all other samples in the study46. 
Normalization of the data was performed with RMA. In general, if genes were represented by two or 
more probe sets, the probe set with the highest mean expression was used for all further microarray 
data analyses. Mapping between probeset and genes were conducted with the appropriate 
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Bioconductor packages. Target genes for the TP63∆N network were downloaded from the “Pathway 
Interaction Database” (PID)53 and hierarchically clustered (method: Ward, distance measure: Euclidian). 
Gene set enrichment analysis was conducted with DAVID or MSigDB v6.0. All following microarray data 
sets are Illumina-based and were VST-transformed followed by quantile normalization as implemented 
in lumi54. Microarray data set of hPDAC cell lines (accession number GSE17891) was downloaded from 
Gene Omnibus Expression database. PDAC classifier genes and EMT hallmark gene set were used as 
described above. For the comparison of human wild-type pancreatic tissue and hPDAC cell lines, 
limma55 was used for detection of differential expression between groups. Differentially expressed genes 
were determined with an alpha level threshold of 5%. The PACA-AU ICGC data set was downloaded 
from the repository https://dcc.icgc.org/repositories. Samples that met the following criteria were 
selected for further analyses: (i) Bailey HistoSubtypes “PDA-Adenosquamous carcinoma” or “Pancreatic 
Ductal Adenocarcinoma” with available subtype information from Bailey et al.7 and (ii) ICGC WHO 
Grading “Undifferentiated carcinoma”. Only representative samples, as judged by cluster analysis, from 
this group were selected for downstream analysis. ANOVA was performed across six defined subgroups 
of pancreatic cancer: (i) undifferentiated pancreatic carcinoma, (ii) adenosquamous pancreatic 
carcinoma and (iii-vi) PDAC sub-stratified in pancreatic progenitor, immunogenic, squamous and ADEX 
subtypes. Genes with an adjusted P-value ≤0.05 were hierarchically clustered (method: Ward, distance 
measure: Manhattan) and the resulting cluster tree was computationally stratified into five sub-clusters. 
Genes within subclusters were used for gene enrichment analysis as described above. Seventeen PK-
PB primary cultures established elsewhere13 were submitted to RNA extraction and subsequent gene 
expression profiling analysis on a MouseWG-6 v2.0 Expression BeadChip (Illumina). The 5% of genes 
with the highest variability across all samples were used for hierarchical clustering using the ward 
method for aggregation of samples. Limma was used as described above. A gene was called 
differentially expressed if the adjusted P-value was ≤0.05 and the log2-fold was at least 0.8.  
Quantitative transposon insertion site sequencing (QiSeq). Aforementioned gDNA samples of the 
PK-PB pancreatic cancer cell cultures13 were sequenced for transposon integration sites and 
bioinformatics analyses were performed as described elsewhere56. Transposon integration sites that 
are supported by at least 20 reads and reside in intragenic regions were counted for the computation of 
the mutational burden. For the assessment of the Cdkn2a/NcrucΔHOM status caused by transposon 
insertional mutagenesis, only the top hit of each tumor was considered.  
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KrasG12D induction after lentiviral transduction of hPDAC cell lines. The pINDUCER2057 vector 
system comprising a puromycin resistance gene was used for doxycycline-inducible KRASG12D 
overexpression. Briefly, cDNA of oncogenic KRASG12D (CCDS 8702.1, 35G>A) and GFP were cloned 
into the pINDUCER20 lentiviral vector. Stbl3 bacteria (Thermo Fisher Scientific) were chemically 
transformed and pDNA sequence was verified. For lentivirus production, HEK293FT cells were 
transfected using TransIT®-LT1 (Mirus Bio LLC) with standard virus packaging plasmids and respective 
pINDUCER20 vectors by following manufacturer’s recommendations. Virus-containing supernatant was 
pooled 48h and 72h post transfection, concentrated by polyethylene glycol 6000 precipitation58 and 
stored at -80°C after shock-freezing. 1x105 HUPT3 (COSMIC ID: COSS907285) and PANC0327 
(COSMIC ID: COSS925346) hPDAC cells were transduced in presence of 1µg/mL polybrene and 
selected with puromycin antibiotic. Target gene expression was induced for stated time points by the 
addition of 100ng/µL doxycycline into P/S-free culturing medium. RNA isolation, qRT-PCR and SCRB-
Seq were performed as described above. For differential gene expression analysis, raw sequencing 
data were mapped to the human reference genome (GRCh 38p10). Transcript and gene definitions 
were used according to the ENSEMBL annotation release 87. Group comparisons (KRASG12D vs GFP) 
were conducted with DESeq2.  
Somatic CRISPR/Cas9 gene-editing for tumor clone tracking in mice. Multiplexed gene editing of 
tumor suppressor genes using CRISPR/Cas9 in the pancreas of PK mice was performed as described 
elsewhere30. Primary cultures of induced mPDACs were isolated as described above and monitored for 
the simultaneous presence of epithelial and mesenchymal phenotypes. Enrichment of epithelial and 
mesenchymal cell morphologies was achieved by differential exposition times to trypsin (Thermo Fisher 
Scientific Inc.). Short-term incubation (2-3 min) at room temperature induced detachment of 
mesenchymal cells, while epithelial colonies remained adherent. Both cell fractions were subsequently 
grown to 80% confluency in new flasks. This process was repeated for 3-6 times until homogenous 
epithelial and mesenchymal cell fractions were enriched. Clonal origin of both phenotypes was 
confirmed by targeted amplicon-based next generation sequencing of CRISPR/Cas9-edited loci as 
described earlier30,59. Analyses of the Kras allelic status and mRNA expression were carried out as 
described above.  
Statistics and reproducibility. For each experiment, all statistics were performed as indicated in 
respective Figure legends and Extended Data Figure legends. Statistical testing across all classes was 
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performed to account for multiple testing. Continuous variables were tested for normal distribution. Non-
parametric tests were used for non-normally distributed data. Complex statistical techniques are 
explained in detail in the Methods section. No animals were excluded from any of the cohorts. The 
veterinarian pathologists were blinded during histological grading of primary tumors and metastasis 
screening. The study was of explorative nature. Due to this study design prior knowledge of the expected 
effect-size was not available and no power calculations were conducted.  
Code availability. Source code is available from the authors upon reasonable request.  
Data Availability. Sequence data have been deposited at EBI European Nucleotide Archive (ENA; 
https://www.ebi.ac.uk/ena) under accession number PRJEB23787. Microarray data have been 
deposited in the Gene Expression Omnibus (GEO; https://www.ncbi.nlm.nih.gov/geo/) under accession 
number GSE107458. All data are available from the corresponding author upon reasonable request. 
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Extended Data Figure 1 | Mutational patterns, karyotype complexity and structural alterations in 
primary PDAC. a, Single nucleotide variants (SNVs) and indels in primary PDAC cultures derived from 
38 KrasG12D (PK) mice, as detected by whole-exome sequencing. Recurrently mutated genes that are 
frequently altered in human cancers and/or genome-wide pancreas-specific transposon screens are 
indicated. b, Frequency of somatic base substitutions based on trinucleotide context in mouse (n=38 
PK mice) and human PDAC (n=51 patients, data used for analysis from 6). b-f, Mutation spectra defined 
by trinucleotide contexts around base substitutions as detected by whole-exome sequencing show 
similar patterns in PK mice (n=38) and in relevant human pancreatic cancer cohorts. Base substitutions 
were extracted from BAM, VCF or MAF files from: b, Witkiewicz et al.6, c, Bailey et al.7, d, TCGA-PAAD, 
e, Barretina et al.46 and f, Alexandrov et al.47. Additional information regarding the analysis of each 
cohort is provided in Supplementary Table 2. g, Mutational signatures in mouse and human pancreatic 
cancer cohorts. Information on mutational signatures was used from Alexandrov et al.47, who identified 
21 mutational signatures operative in human cancer. The „deconstructSigs“ tool was used to determine 
the composition of the given set of 21 mutational signatures in each pancreatic cancer cohort. Extraction 
of mutational signatures strongly depends on SNV load per tumor. Due to the low mutational burden of 
mPDACs from PK mice (median of 18 SNVs per tumor as detected by WES), the analyses of mutational 
signatures could not be performed at the level of individual tumors. We have therefore investigated the 
contribution of each of the 21 mutational signatures to the SNV spectrum at the cohort-level (see 
Methods). Signature 1, reflecting age-associated C>T transversions at NCG trinucleotides, was the only 
signature consistently identifiable in all cohorts of human and mouse pancreatic cancer. In comparison 
to human cohorts, PK mice show C>G substitutions at GCC trinucleotides that cannot be attributed to 
one of 21 mutational signatures. Note that mutations at the GCC motif are not a general phenomenon 
of PDAC from PK mice, since only 4 samples are predominantly contributing to this peak. h-i, 
Representative M-FISH karyotypes with no or few karyotypic changes are shown for a diploid (40 
chromosomes) and tetraploid mouse PDAC (81 chromosomes). Tumor 9591 shows gain of chr14. j, 
Representative karyotype of a complex diploid mPDAC genome with aneuploidy and translocations (46 
chromosomes). Both copies of chr4 are involved in translocations: der(4)t(4;10) and der(4)t(4;16); likely 
affecting Cdkn2a. Further structural alterations and copy number changes are: +5, der(5)t(4;5)*2, +6, 
+7, +8, del(9), +14, del(14), der(16)t(5;16), +17. k, Representative example of a complex tetraploid 
mPDAC karyotype (77 chromosomes). Structural alterations are: der(1)t(1;11), dic(9;9), der(11)t(1;11), 
and der(14)t(14;19). Single chromosomal copy number changes are: +2, -3, -9, -10, -11, -13, -14, +15 
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and +19. Del, deletion; der, derivative chromosome; dic, dicentric chromosome; t, translocation; „-“, 
chromosome loss; „+“, chromosome gain. l, (Extension to Fig. 1c.) Circos plot shows CNAs assessed 
by aCGH as well as translocations and ploidy states detected by M-FISH in 38 primary PDACs derived 
from PK mice (n=38). CNAs for each mPDAC are displayed as log2 difference from tail control. 
Frequencies of translocations per chromosome are indicated in green in the inner circle of the graph. 
Connecting lines indicate individual translocations and involved chromosomes. On chr4, genomic 
alterations frequently involve Cdkn2a or Ncruc, a Non-coding regulatory region upstream of Cdkn2a 
(27/38 cancers with homozygous and 10/38 with heterozygous inactivation of Cdkn2a and/or Ncruc). 
Only one cancer remained Cdkn2aWT. The target of copy number changes on chr6 is KrasG12D, either 
through arm level gain or focal amplification. In addition, primary mPDAC of PK mice exhibited recurrent 
genetic amplifications affecting other known oncogenes, such as Myc or Yap1, or Nfkb2, a novel 
oncogenic PDAC driver identified in this study (see also Fig. 2e,f and Extended Data Figure 4).  
 
Extended Data Figure 2 | Characterization of complex rearrangements in PDAC from PK mice 
and statistical inference of chromothripsis based on whole genome sequencing (WGS). a-n, 
Copy number profiles of chromosomes with complex rearrangements (defined as n≥10 CNAs per 
chromosome) from primary mPDAC cell cultures as detected by aCGH. A total of 14 mPDACs had 
chromosomes with complex rearrangements. a-i, Nine primary mPDACs show copy number patterns 
characterized by heterozygous deletions and oscillation of copy number around few states, indicating 
chromothripsis as the underlying mechanism. g, mPDAC-S821 was subjected to whole genome 
sequencing for the inference of chromothripsis using previously established criteria14 (see Fig. 1d and 
Extended Data Figure 2p-w). j-m, Four primary mPDACs showed complex rearrangements with multiple 
copy number states on chr4, likely acquired through progressive/sequential rearrangement cycles. n, 
Cancer 5671 carries a complex rearrangement on chr15 characterized by oscillating copy number states 
and 3 prominent focal amplifications, of which one contained the Myc oncogene. Myc amplification is 
most likely the result of double minute chromosome formation during chromothriptic rearrangement of 
chr15. o, Comparison of age at tumor diagnosis in Cdkn2a∆HOM-deleted cancers with (n=10) or without 
(n=15) complex clustered chromosomal rearrangements (n≥10 CNAs/chromosome). Complex clustered 
rearrangements are associated with significantly shortened time to tumor diagnosis, indicating 
accelerated tumor evolution through genetic crisis. Two-sided log-rank test. p, Criteria proposed by 
Korbel et al.14 were tested for the inference of chromothripsis. Circos plot displays SNP ratio (inner 
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circle, red dashed line indicating heterozygosity), CNV (outer circle, blue area indicating deletion, red 
amplification) and structural variations (colors as in v) as detected by WGS. Chr4 shows a complex 
deletion pattern and massive rearrangements associated with loss of one copy of Cdkn2a. The second 
copy of Cdkn2a is focally deleted. In addition, a balanced translocation of a ~200Kb segment from 
trisomic chr6 to chr4 and a far smaller segment of chr4 into chr6 was detected. The Kras locus is not 
directly affected by this inter-chromosomal translocation. LOH, CNAs and rearrangements are not 
detected on other chromosomes. q, In a chromothriptic model, DNA breakpoints tend to cluster on a 
chromosome. Testing against an exponential distribution (parameter λ derived from mean of observed 
distance between adjacent breakpoints), revealed significantly shorter distances than expected in a 
progressive model (n=146 breakpoints). P<10-12; χ²-goodness-of-fit test. r, In a progressive model of 
acquisition of massive rearrangements, copy number states tend to be more complex than in the 
chromothriptic. Monte Carlo simulations were used to generate a progressive evolution model with 
sequential accumulation of observed rearrangements (n=100 simulations per number of SVs). mPDAC 
S821 showed fewer copy number states on chr4 than expected in the progressive model. Mean is 
indicated as a black point and lines represent the 95% CI. s, Chromothriptic tumors typically feature 
interspersed loss and retention of heterozygosity. Accordingly, there was a high overlap between 
deleted regions and LOH segments on chr4 (Jaccard index (J) = 0.99). t, In a chromothriptic model, 
DNA shattering typically occurs on a single haplotype. M-FISH showed that significant loss of 
chromosomal content occurred on only one copy of chr4. u, To show random chromothriptic DNA 
shattering and re-joining, observed segments (n=73) were re-ordered by running Monte Carlo 
simulations (n=103) that generate a background probability distribution. S821 segment order lies within 
the chromothriptic null model. Two-sided P=0.78. v, All 4 SV-types are uniformly distributed in a 
chromothriptic tumor model. P=0.43; χ²-goodness-of-fit test. w, In a chromothriptic model, paired end 
connection types (as given by the SV-type) induce an alternating sequence of DNA segment ends when 
ordered according to the genomic position on the original chromosome. Tendency towards this 
alternating 3’-to-5’ pattern of rearranged DNA segment ends (n=146) was tested by using right-sided 
Wald-Wolfowitz runs test. P<10-12.  x, Mutation clusters in relation to breakpoint junctions involved in 
chromothripsis are shown as rainfall plot for primary PDAC from PK mouse S821. Each dot represents 
a single somatic nucleotide variation (SNV) and is ordered on the x-axis according to its position in the 
mouse genome. The distance of each SNV to the previous SNV in the genome is shown on the y-axis. 
The coloring of individual SNV dots indicates the type of nucleotide substitution. y, Chr4 “zoom-in” from 
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(x). Breakpoint junctions are shown according to their genomic position on chr4. No mutation clusters - 
neither in absence nor in combination with breakpoint junctions - were detected, consistent with 
chromothripsis involving end joining DNA repair mechanisms. This is in contrast to other complex 
rearrangement types, such as chromoanasynthesis, which arise through replication-based mechanisms 
with breakpoint-associated high mutation rates (e.g. kataegis). 
 
Extended Data Figure 3 | Specificity, timing, mechanisms and impact of KrasG12D gene dosage 
alterations on gene expression in pancreatic tumorigenesis. a, Overlay of copy number profiles of 
primary mPDAC cell cultures from PK mice (n=38) as determined by aCGH. Y-axis shows frequency of 
a genomic region to be amplified (up) or deleted (down) in the cohort, with Cdkn2a and Kras loci being 
most frequently affected by CNAs. b, Prevalence of LOH in primary mPDAC cell cultures from PK mice 
(n=38) based on whole exome sequencing (WES) data. A chromosome was considered to be affected 
by LOH if the SNP frequency was shifted to ≤0.1 or ≥0.9 in a segment with a size ≥200kb. LOH on chr4 
is frequently the consequence of heterozygous deletions involving the Cdkn2a locus. By contrast, LOH 
on chr6 is predominantly copy number neutral and linked to increased KrasG12D gene dosage. Chr4 
(home of Cdkn2a) and chr6 (home of Kras) show markedly increased rates of LOH as compared to all 
other chromosomes reflecting their functional importance during tumorigenesis. c-h, Genetic 
mechanisms of KrasG12D gene dosage alterations as identified by aCGH, M-FISH and whole exome 
sequencing (WES) in pancreatic cancers from PK mice. The observed types of increased KrasG12D gene 
dosage were: (i) focal gain (affecting ≤50% of the chromosome length), arising either through replication-
based mechanisms (2 cases, one with high-level KrasG12D amplification [shown in c] and one with low 
level amplification) or translocation and subsequent amplification of the translocated chromosome (one 
case [shown in d]), (ii) arm-level gain (affecting ≥50% of the chromosome length) arising through mitotic 
errors (7 cases of whole-chromosome gain [example shown in e], occasionally [2 cases] with 
concomitant intra-chromosomal deletions or translocations not affecting Kras [example shown in f]) and 
(iii) copy-number neutral LOH (CN-LOH, KrasG12D homozygosity, acquired uniparental disomy), arising 
either through mitotic recombination (affecting parts of chr6 [shown in g]) or chromosomal 
missegregation (duplication of KrasG12D-mutant chr6 and loss of wild-type chr6 [shown in h]). c, mPDAC 
S134 shows a high-order focal amplification of KrasG12D. Sharp borders, small size of the amplification 
(600kb) and strong increase in copy number (4x) indicate that KrasG12D was amplified through multiple 
cycles of repeated template-switching by a replication-based DNA repair mechanism. KrasG12D mutant 
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allele frequency is 89.1%. d, Tumor 4706 carries a focal amplification of KrasG12D. M-FISH analysis 
revealed that the mutant KrasG12D allele (chr6) was likely first affected by a reciprocal translocation of 
chr4 and chr6, resulting in two rearranged chromosomes: Der(4)T(4;6) and Der(6)T(4;6). Subsequently, 
Der(4)T(4;6) was missegregated through mitotic error resulting in focal gain of the KrasG12D locus. 
KrasG12D mutant allele frequency is 72.2%. e, mPDAC R1035 shows ‘classical’ whole chromosome gain 
(trisomy) of chr6, which was likely generated through mitotic error/missegregation. The KrasG12D mutant 
allele frequency is 69.8%. f, In tumor 8442 arm-level gain of KrasG12D was likely generated through 
mitotic missegregation of chr6. Intra-chromosomal deletion on one of three chromosomes (19.6Mb) 
does not affect Kras. KrasG12D mutant allele frequency is 66.4%. Asterisk, chr6 with reduced length 
resulting from intra-chromosomal deletion. g-h, mPDAC 16992 and B590 display copy-number neutral 
LOH (CN-LOH) leading to increased KrasG12D gene dosage. KrasG12D mutant allele frequency is 99.2% 
and 96.3%, respectively. The SNP pattern of chr6 in mPDAC 16992 reveals that the whole chromosome 
is affected by CN-LOH indicating chromosome missegregation (duplication of the KrasG12D-mutant chr6 
and loss of wild-type chr6) as the underlying mechanism. By contrast, in mPDAC B590 only a partial 
region of chr6 is affected by CN-LOH, therefore probably resulting from mitotic recombination. i, Allele-
specific KrasG12D mRNA expression in KrasG12D-HET (n=12) vs. KrasG12D-iGD (n=26) primary PDAC cell 
cultures from PK mice as detected by combined analysis of amplicon-based RNA-Seq (proportion of 
mutant/wild-type Kras mRNA) and 3’-prime pA RNA-Seq (amount of total Kras mRNA, but not the 
proportion of mutant/wild-type Kras mRNA due to sequencing of 3’-prime transcript ends) (see Methods 
section). This figure is related to Fig. 2b. ***P≤0.001, two-tailed Mann-Whitney test; bars, median. j, 
Mutant KrasG12D mRNA levels in Cdkn2a/Ncruc∆HET/WT (n=11) vs. Ckdn2a/Ncruc∆HOM (n=27) primary 
PDAC cell cultures from PK mice as detected by combined amplicon-based RNA-Seq and 3’-prime pA 
RNA-Seq. This figure is related to Extended Data Figure 5f. ***P≤0.001, two-tailed Mann-Whitney test; 
bars, median. k, Mutant KrasG12D mRNA levels in transcriptional clusters of mPDAC from PK mice 
(C2a/b/c/C1, n=5/7/6/15) as detected by combined amplicon-based RNA-Seq and 3’-prime pA RNA-
Seq. This figure is related to Fig. 5d. P=1.6*10-5, two-sided Pearson correlation; bars, median. l-n, 
Interphase fluorescence in situ hybridization (FISH) for the analysis of copy-number and ploidy states 
at the KRAS locus on chr12 in human pancreatic intra-epithelial neoplasia (PanIN) with KRASG12 variant 
allele frequencies (VAFs) of ~100%. KRASG12 VAFs are indicated above each FISH profile as detected 
by amplicon-based deep sequencing. A VAF of ~100% can be caused either by loss of the wild-type 
KRAS-locus (hemizygosity of KRASG12-MUT: one KRASG12-MUT allele per cell) or by CN-LOH (acquired 
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uniparental disomy; homozygosity of KRASG12-MUT: two KRASG12-MUT alleles per cell). All samples show 
a diploid genome as suggested by CEN12 (two red signals per nucleus). Neither loss of one KRAS 
allele nor monosomy of chr12 was observed providing evidence for CN-LOH and increased KRASG12-
MUT gene dosage in hPanIN. Scale bars, 2.5µm; CEN12, centromere probe chr12. 
 
Extended Data Figure 4 | Enrichment for amplification of alternative oncogenic drivers in 
mPDACs of PK mice with KrasG12D-HET status. a-b, Two primary mPDACs with strong focal Myc 
amplification on chr15 are shown, as detected by aCGH. Red dashed line indicates no copy number 
change. c-d, Focal copy number gains targeting the Yap1 locus on chr9 in primary mPDACs 4072 and 
9203 as revealed by aCGH. e, Chr19 was also frequently subject to arm-level gain (see Fig. 1c and 
Extended Data Figure 1l). Primary mPDAC of PK mouse 4072 harbors a focal gain on chr19 containing 
20 genes: 9130011E15Rik, Gm6813, Hps6, Ldb1, Pprc1, Nolc1, Elovl3, Pitx3, Gbf1, Nfkb2, Psd, Fbxl15, 
Cuedc2, Tmem180, Actr1a, Sufu, Trim8, Arl3, Sfxn2, D19Wsu162e. f, Cross-species analyses revealed 
that the orthologous region on human chr10 is also subject to recurrent amplifications in human PDAC 
(8 out of 109 hPDACs have focal amplifications; data from Witkiewicz et al.6). Of the 20 mouse genes, 
sixteen could be assigned to orthologues in humans. Further analyses revealed that only two genes, 
NFKB2 and PSD, are within the minimal overlapping region of recurrent amplification (data from6 and 
oncoplot from cBioPortal60,61). g, NFKB2, but not PSD, shows medium protein expression in exocrine 
glandular cells of normal pancreatic tissue, as detected by immunohistochemistry (IHC, data from 
TheHumanProteinAtlas62). h, NFKB2 is highly expressed in 17% (2/12) of stained hPDAC biopsies as 
shown by IHC. In contrast, there was no PSD expression in any of the analyzed pancreatic cancers 
(0/12). Protein expression data was used from TheHumanProteinAtlas62. 
 
Extended Data Figure 5 | Characterization of Cdkn2a (chr4) alterations and correlation with 
KrasMUT gene dosage variation and mRNA expression in mouse and human PDAC. a-d, Cdkn2a 
alteration on mouse chr4 can occur through arm-level, complex or focal loss as well as uniparental 
disomy (see Figure 3). In addition, chr4 is frequently involved in inter-chromosomal translocations. 
Examples of representative karyotypes of primary pancreatic cancer cultures derived from PK mice with 
translocations involving chr4, likely affecting the Cdkn2a locus. In all 4 cases, chr4 translocations were 
found in all 10 metaphase spreads of each cancer, indicating their early acquisition during tumor 
evolution. a, mPDAC 4706 with diploid karyotype: 42, XX, del(X), +2, der(2)t(2;4)is(2;4), der(4)t(4;6)*2, 
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+der(4)t(2;4), der(6)t(4;6). b, mPDAC 4900 also features a diploid karyotype: 41, XX, der(X)is(X;4), 
der(4)is(4;8), del(4), +6, der(8)t(4;8). c, mPDAC 5123 underwent polyploidization, after translocation of 
chr4 with chr1 and an deletion on the other copy: 78, XXXX, -1, del(1)*2, -2, +4*2, der(4)t(1;4)*3, 
del(4)*3, -5, -7, -9, +15, -17, +18 d, mPDAC 8349 shows a diploid karyotype: 40,XX, der(4)t(3;4), 
der(4)t(4;13), +del(4), der(13)t(4;13). e, KrasG12D variant allele frequencies detected by amplicon-based 
deep sequencing of the Kras locus are higher in Cdkn2a/Ncruc∆HOM mPDAC (n=11) as compared to 
Cdkn2a/Ncruc∆HET/WT (n=27) pancreatic cancers. All cancers are from PK mice. Blue dots indicate 
tumors with complete Ncruc deletion. ***P≤0.001, two-tailed Mann-Whitney test; bars, median. f, Allele-
specific expression of mutant KrasG12D mRNA is increased in primary tumors from PK mice with 
Cdkn2a/Ncruc∆HOM (n=27) background in comparison to Cdkn2a/Ncruc∆HET/WT (n=11) cancers. Primary 
mPDACs with homozygous loss of Ncruc are highlighted in blue. KrasG12D expression was analyzed by 
combining amplicon-based RNA-Seq and qRT-PCR (as described in the Methods section). **P=0.003, 
two-tailed Mann-Whitney test; bars, median. g, KRASMUT variant allele frequencies based on WES in a 
published dataset of microdissected human PDAC (Witkiewicz et al., reduced stromal content) was 
analyzed with respect to CDKN2A and TP53 status. KRASMUT allele frequency was higher in 
mutated/homozygous deleted CDKN2A and/or TP53 (CDKN2AMUT/∆HOM/TP53MUT/∆HOM; hPDACs as 
compared to cancers with CDKN2A∆HET/WT/TP53∆HET/WT status (from left: n=28, n=14, n=28, n=30). Two-
sided rank-based ANOVA (P=5.8*10-6); post hoc testing with two-sided Tukey honest significant 
difference test, *adj. P≤0.05, ***adj. P≤0.001; bars, median. h, Fraction of the genome altered by copy 
number changes detected by aCGH in primary mPDACs of PK (n=38), PKC (n=16) and PKP (n=16) 
mice. PKP mice show a significantly increased CNA load as compared to PKC mice. Two-sided rank-
based ANOVA (P=0.01); post hoc testing with two-sided Tukey honest significant difference test, **adj. 
P=0.009, adj. P-values for group wise comparisons are shown; bars, median. Del, deletion; der, 
derivative chromosome; is, insertion; t, translocation; „-“, chromosome loss; „+“, chromosome gain. 
 
Extended Data Figure 6 | Complete Cdkn2a barrier loss precedes KrasG12D-iGD in primary mPDAC 
of PK mouse 53704. Copy number alterations at chr4 (Cdkn2a) and chr6 (Kras) in mPDAC 53704 and 
corresponding metastases, as detected by aCGH (top) and whole-exome sequencing based SNP 
pattern analysis (bottom). The primary cancer and both liver metastases display identical focal deletions 
of Cdkn2a and similar SNP patterns on chr4 revealing that all lesions share the same ancestor cell with 
complete Cdkn2a loss. By contrast, SNP analysis on chr6 revealed discordant patterns in the primary 
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mPDAC and both metastases. Li2 shows partial LOH of a distal region on chr6 involving the Kras locus, 
while LOH in Li3 involves the whole chr6. This explains the step-wise LOH pattern observed on chr6 in 
the primary mPDAC. The graphic on the right shows the combined interpretation of CNV/LOH profiles, 
which suggests the following sequence of genetic events during tumor evolution: The initial KrasG12D 
mutation was followed by focal deletion of one copy of Cdkn2a. In a subsequent genetic event, the 
second copy of Cdkn2a was lost by chr4 missegregation and copy-number neutral LOH. Complete 
barrier loss allowed for convergent evolution of increased KrasG12D gene dosage through copy-number 
neutral LOH and gave rise to independent metastases in the liver. Note: A major obstacle for equivalent 
human studies is the limited availability of human matched primary/metastases samples, particularly of 
treatment naive ones. We performed cross-species analyses using data from a recent study, which 
analyzed human treatment-naive metastatic PDACs by whole-genome sequencing8 and provided 
CDKN2A and KRAS copy number data for matched primaries/metastases from 3 patients. In one patient 
the sequential order of CDKN2A deletion and KRAS amplification could be reconstructed: homozygous 
CDKN2A deletions were identical in all primaries and metastases, whereas there were 5 different KRAS 
gains in the 6 metastases. This suggests convergent evolution of mutant KRAS gene dosage gain upon 
homozygous CDKN2A loss in this patient, in line with similar data in large series of mouse cancers and 
their metastases (see Figure 3e).  
 
Extended Data Figure 7 | Transcriptome-based subtyping of human primary pancreatic cancer 
and classification of human PDAC cell lines and primary PDAC cell cultures from PK mice. a-c, 
Independent cross-comparison of transcriptional classification systems from Collisson et al.28, Moffitt et 
al.29 and Bailey et al.7. Collisson et al. performed PDAC microdissection and defined 3 transcriptional 
subtypes: classical, quasimesenchymal (QM) and exocrine-like. Moffitt et al. defined 2 subtypes 
(classical, basal-like) using (i) virtual separation of tumor and non-tumor gene expression patterns, (ii) 
transplantation studies and (iii) human PDAC cell lines; and proposed that the exocrine-like signature 
stems from exocrine pancreatic cells, rather than from the cancer cells. Bailey et al. used bulk tumors 
and defined 4 subtypes (pancreatic progenitor, immunogenic, squamous, aberrantly differentiated 
endocrine exocrine [ADEX]). RNA-Seq data from PDAC and adenosquamous pancreatic carcinoma 
from Bailey et al. was used for cross-comparison of classification systems. Other histological subentities 
of pancreatic cancer were excluded (e.g. IPMN, MCN, acinar cell carcinoma). The Bailey subtyping for 
this dataset was available. a, Unbiased hierarchical clustering of primary pancreatic cancer samples 
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(n=71) from Bailey et al. using Collisson classifier genes. b, Subtyping of primary pancreatic cancer 
samples (n=71) from Bailey et al. using classifier genes defined by Moffitt et al. c, Consensus clustering 
based on analyses performed in a/b. There is considerable overlap between at least two subtypes, 
which are in large parts captured by the initially proposed Collisson classical and quasimesenchymal 
(QM) signatures (which are also detected in mouse and human PDAC cell lines; see Extended Data 
Figure 7e-h). The Bailey classification (based on bulk tissue analyses) suggests that Collisson classical 
cancers (microdissected cancer tissue) can be further sub-stratified in some with and some without a 
strong immune cell infiltration. The Moffitt classification suggests that the Collisson exocrine-like 
signature (Bailey ADEX subtype) stems from “contaminating” healthy exocrine pancreatic cells, based 
on the evidence described above. Given that the Collisson exocrine-like signature was derived from 
microdissected PDAC, such “contamination” is only conceivable, if exocrine-like signature genes were 
dramatically higher expressed in pancreatic acinar cells as compared to PDAC cells. d, Volcano plot 
showing strongly upregulated expression of exocrine-like genes in human wild-type pancreas (13 to 241 
fold; median: 183-fold upregulation). Note that 15 out of 19 exocrine-like signature genes (red dots) are 
among the top50 genes upregulated in human wild-type pancreas (n=3) as compared to hPDAC cell 
lines (n=30) (y axis is calculated on Benjamini-Hochberg adj. P-values derived from R package limma 
[see Methods section]). Although these data do not exclude the existence of exocrine-like PDACs, they 
support the possibility that “contamination” with few acinar cells can impose an exocrine-like signature 
on a cancer. This might explain why human or mouse PDAC cell lines don´t cluster into the exocrine-
like subtype (see also Extended Data Figure 7e-f below). e, Hierarchical clustering of microarray-based 
expression profiles using Collisson identifier genes28 on human PDAC cell lines (n=19, GEO series 
GSE17891). As also described earlier by Collisson et al., only two subtypes can be detected in human 
cell line collections: classical and quasimesenchymal (QM). Of note, the most prominent change in the 
QM cell lines is downregulation (extinction) of the classical assigner genes, whereas expression of QM 
classifier genes is quite variable. We therefore also use here the terms classical and non-classical. f, 
Projection of the Collisson classifiers on mouse PDAC cell culture transcriptomes (n=33) also identified 
classical and non-classical subtypes. The non-classical subtype contained a subset of mPDAC cell 
cultures from cluster C2a/b/c (epithelial morphology; equivalent of human QM) and all cluster C1 
mPDACs (mesenchymal morphology; "M" cluster). g, Application of a human EMT hallmark gene set52 
for hierarchical clustering of expression profiles from primary PDAC cultures (PK mice; n=33) resulted 
in a separation of C1 (mesenchymal) and C2a/b/c (epithelial) cell lines. h, Projection of the EMT hallmark 
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gene set on human PDAC cell line transcriptomes (n=19, GEO series GSE17891) did not result in a 
clear separation of samples, indicating underrepresentation of the mesenchymal M subtype (equivalent 
to murine C1/"M") in available human cell line collections. As shown in Extended Data Figure 9b, 
however, the EMT signature is detectable in undifferentiated human pancreatic carcinoma, which is the 
human equivalent of the mesenchymal mouse PDACs in C1.  
 
Extended Data Figure 8 | Functional analyses to study the role of KrasG12D gene dosage increase 
in EMT. a-d, Multiplexed somatic CRISPR/Cas9 mutagenesis for phylogenetic tracking of 
epithelial/mesenchymal mPDAC clones in vivo. a, Graphic demonstrates major steps of multiplexed 
gene editing by pooled delivery of CRISPR/Cas9 vectors, each targeting a different tumor suppressor 
gene in the pancreas of PK mice. Electroporation-based transfection induces low-frequency mosaic 
vector delivery (average of 120 cells per pancreas are transfected) to induce clonal tumors. Primary 
tumor cell cultures were screened for the simultaneous presence of epithelial and mesenchymal cells. 
Two such cancers were identified (mPDACs from mouse 021 and mouse 901) and subjected to 
differential trypsinization in order to enrich for each morphology. b, Amplicon-based deep sequencing 
of all sgRNA-targeted loci revealed identical indel patterns in both epithelial/mesenchymal culture pairs. 
This shows (i) that epithelial and mesenchymal cells originate from the same clone and (ii) that the 
CRISPR-induced mutations are not contributing to the differential phenotype. c, KrasG12D variant allele 
frequencies in epithelial and mesenchymal cell cultures from mPDAC 021 and mPDAC 901, as detected 
by amplicon-based deep sequencing. Both cancers had increased KrasG12D expression in mesenchymal 
cells (see Fig. 5e). In mPDAC 021 this is due to selective amplification of the KrasG12D allele in 
mesenchymal cells. In mPDAC 901 genetic KrasG12D amplification was not observed, suggesting 
induction of increased Kras expression in mesenchymal cells by other mechanisms. d, Gene set 
enrichment analysis using “Molecular Signatures Database” (MSigDB) of differentially regulated genes 
in mesenchymal versus epithelial mPDACs based on RNA-Seq. Mesenchymal clones of mPDAC 021 
and mPDAC 901 show an upregulation of genes involved in “MAPK signaling pathway” and “EMT” as 
compared to the corresponding epithelial clones, in line with increased KrasG12D gene expression (a full 
list of enriched gene sets is provided for comparisons in Supplementary Table 15). FDR-adjusted P-
values are shown on y axis. Representative data from one experiment are shown. e-g, induction of 
EMT-like transcriptional programs by KRASG12D overexpression in human PDAC cell lines. e, Graphic 
of experimental workflow. Two human PDAC cell lines (HUPT3 and PANC0327) with homozygous 
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CKDN2A loss (CDKN2A∆HOM) and heterozygous KRASMUT (KRASMUT-HET) status were transduced with 
lentivirus carrying doxycycline-inducible KRASG12D or GFP-control expression constructs. KRASG12D or 
GFP expression was induced by adding doxycycline for 1, 3 and 5 days. f, Gene set enrichment analysis 
using “Molecular Signatures Database” (MSigDB) of differentially regulated genes in KRASG12D- versus 
GFP-induced hPDAC cell lines HUPT3 and PANC0327 based on RNA-Seq. Upon doxycycline 
treatment, both hPDAC cell lines showed a consistent upregulation of genes involved in “KRAS signaling 
up” and “EMT” (a full list of enriched gene sets is provided for both cell lines in Supplementary Table 
16). FDR-adjusted P-values are shown on y axis. g, Expression of marker genes for epithelial (CDH1) 
or mesenchymal (VIM) cell differentiation and invasion/matrix disassembly (MMP1) was validated by 
qPCR (normalized to GAPDH and PPIA). In line with RNA-Seq data KRASG12D-induced cells show an 
increased expression of the mesenchymal marker gene VIM, increased expression of MMP1 and 
reduced levels of epithelial marker gene CDH1. *P≤0.05, **P≤0.005, ns=not significant, two-tailed t-test; 
bars=mean; error bars=SEM.  
 
Extended Data Figure 9 | Transcriptional profiles of human undifferentiated pancreatic 
carcinomas are enriched for signatures of oncogenic signaling intensification and EMT but not 
for activation of TP63∆N transcriptional network. a, Primary pancreatic tumors from PK mice with a 
mesenchymal phenotype (C1 cluster, n=15) are almost exclusively classified as 
undifferentiated/sarcomatoid by histopathological evaluation and tend to have a reduced age at 
diagnosis when compared to epithelial (C2a/b/c cluster, n=18) tumors (histopathological grade 1 to 3 
[G1-G3]). This aggressive behavior of undifferentiated pancreatic carcinoma is also observed in human 
patients and is associated with worse clinical outcome33. P-value calculated by two-sided log-rank test. 
b, Comparison of publically available expression profiles of human undifferentiated pancreatic 
carcinoma (n=4), PDAC (WHO grade 1 to 3 [G1-G3], n=64) and adenosquamous pancreatic carcinoma 
(n=7). Human samples with the above histopathological characteristics for which expression-based 
subtype information from Bailey et al.7 was available were used and complemented with available 
undifferentiated pancreatic carcinomas from the ICGC PACA-AU cohort (Supplementary Table 18). 
Other histological subentities of pancreatic cancer were excluded (e.g. IPMN, MCN, acinar cell 
carcinoma). ANOVA was performed to select genes which are differentially expressed in at least one of 
the six defined subgroups of pancreatic cancer: (i) undifferentiated, (ii) adenosquamous pancreatic 
carcinoma and (iii-vi) PDAC (G1-G3) sub-stratified in pancreatic progenitor, immunogenic, squamous 
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and aberrantly differentiated endocrine exocrine subtypes (ADEX) Bailey subtypes. Differentially 
regulated genes were used for unbiased hierarchical clustering of these pancreatic cancer 
transcriptional profiles. Five sub-clusters of co-regulated gene expression could be identified according 
to the cluster tree on the y-axis (separated by white horizontal bars in the heatmap). Gene set 
enrichment analysis using “Molecular Signatures Database” (MSigDB) was performed for individual sub-
clusters and terms related to predominating gene sets/pathways are annotated for each cluster on the 
right (full list provided in Supplementary Table 17). Undifferentiated pancreatic carcinomas cluster 
together and are associated with (i) upregulation of genes in cluster 3 (containing MAPK signaling 
pathway and gene sets relevant during embryonic development or EMT) and (ii) downregulation of 
genes in clusters 2 and 5, which contain gene sets related to epithelial cell differentiation, embryonic 
development or metabolic signatures. This reflects the pathway enrichment signature in the equivalent 
undifferentiated (mesenchymal) mouse PDACs (cluster C1/"M" in PK mice; see Extended Data Figure 
7g) and provides further support for the link between KRAS signaling intensification, EMT and the 
undifferentiated tumor phenotype. The immunogenic PDAC subtype showed high expression of cluster 
4 genes, which was also strong (even elevated) in undifferentiated pancreatic carcinomas, suggesting 
an increased immune cell infiltration in undifferentiated carcinomas. Cluster 1 contained gene sets 
related to cell proliferation/cell cycle, squamous differentiation and TP63∆N transcriptional targets, 
which were most highly overexpressed in pancreatic carcinomas with adenosquamous histology. 
Undifferentiated pancreatic carcinomas did not show activation of the TP63∆N transcriptional targets. 
This suggests that activation of TP63∆N transcriptional targets is not causally linked to KRAS signaling 
intensification and EMT (see also Extended Data Figure 9c-d, showing a lack of association of 
undifferentiated carcinomas withTP63∆N transcriptional network activation). c, Unbiased hierarchical 
clustering of human pancreatic carcinomas with adenosquamous histology (n=7) as well as PDACs 
(WHO grade 1 to 3 [G1-G3], n=64) and undifferentiated pancreatic carcinomas (n=4) (sample set as in 
Extended Data Figure 9b) using a list of validated TP63∆N transcriptional targets53. Pancreatic cancers 
with adenosquamous differentiation were significantly enriched in a cluster showing increased TP63∆N 
transcriptional network activity (P≤0.001, two-sided Fisher’s exact test, OR 130, 95% CI 11.6-1452). 
Undifferentiated pancreatic carcinomas did not contribute to this cluster. In line, pancreatic cancers from 
PK mice did not show differential regulation of the TP63∆N network, reflecting the lack of 
adenosquamous tumors in this cohort (not shown). d, Unbiased hierarchical clustering across solid 
cancers (Cancer Cell Line Encyclopedia, n=856) using the same gene list showed a strong enrichment 
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of tumors with squamous differentiation in the sub-cluster with highest TP63∆N transcriptional network 
expression (P≤0.001, two-sided Fisher’s exact test, OR 28.1, 95% CI 16.4-48.1), in line with the 
observation of Hoadley et al.63 that TP63∆N is a signature for squamous differentiation across cancers.  
 
Extended Data Figure 10 | KrasG12D-gene dosage is a critical determinant of PDAC biology in a 
mouse model with high mutational load. The mutational burden in primary PDAC cultures of PK mice 
was significantly lower as compared to human PDAC studies (see Fig. 1b). To account for this potential 
confounding factor and to test if our discoveries in PK mice also apply in a setting of high mutational 
burden, we used a mouse model combining KrasG12D mutation and PiggyBac transposon-based 
insertional mutagenesis (PK-PB mice13). PK-PB mice show accelerated tumorigenesis as compared to 
PK mice. PK-PB derived tumors had an extensive mutational burden (median of 494 transposon 
insertions per tumor). Primary cultures of PDAC from PK-PB mice (n=17) were subjected to 
comprehensive genetic characterization using aCGH, microarray-based gene expression profiling, 
quantitative transposon insertion site sequencing (QiSeq) and amplicon-based deep sequencing of the 
Kras locus. a, Transcriptome profiles of primary PDAC cultures from PK-PB mice (n=17) were used for 
unbiased hierarchical clustering that resulted in 2 major clusters (C1 and C2), like in PK mice. KrasG12D 
gene dosage status (as determined by aCGH and amplicon-based deep sequencing of the Kras locus) 
and Cdkn2a status (as determined by aCGH and quantitative transposon insertion site sequencing 
[QiSeq]) are indicated below the cluster tree for each individual tumor. Similarly to PK mice, cluster C2a 
was characterized by KrasG12D-HET and Cdkn2a/Ncruc∆HET/WT status, whereas mPDACs in clusters C2b/c 
and C1 had increased KrasG12D gene dosage (KrasG12D-iGD) and were Cdkn2a/Ncruc∆HOM. The genetic 
KrasG12D-status was significantly associated with expression clusters (P=0.01, two-sided Fisher’s exact 
test) providing further evidence that expression clusters are associated with KrasG12D gene dosage. b, 
Prevalence of KrasG12D-iGD in cultures of primary mPDAC (from PK-PB mice) with homozygous (n=12) 
or heterozygous/wild-type (n=5) Cdkn2a/Ncruc status. *P=0.03, two-sided Fisher’s exact test, OR 20.0, 
95% CI 1.4-287.8. c, Gene set enrichment analysis using DAVID of upregulated genes in cluster C1 
(n=5) as compared to cluster C2 (n=12) of primary mPDAC cultures from PK-PB mice. As in PK mice, 
PK-PB tumors in C1 are characterized by upregulation of genes enriched in gene sets describing 
mesenchymal cell differentiation and revealed a strong enrichment for Ras downstream signaling 
pathways (full list in Supplementary Table 19). FDR-adjusted P-values are shown on y axis. Overall, 
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these analyses show that the biological principles discovered in the PK model also apply to pancreatic 
cancers from PK-PB mice with high mutational load.  
 
